Ohio Medicaid does not cover weight loss medication. Drugs prescribed solely to treat obesity are excluded from the Ohio Medicaid pharmacy program, and the exclusion applies whether you are in fee-for-service Medicaid or a managed care plan like CareSource, Molina, or UnitedHealthcare Community Plan. If you want a GLP-1 drug such as Wegovy or Zepbound for weight loss, you will generally need to pay for it yourself.
The Rule Behind the Exclusion
Ohio Administrative Code Rule 5160-9-03 lists “drugs for the treatment of obesity” as non-covered under the state’s Medicaid pharmacy program. Because obesity drugs sit in a non-covered category, they are not eligible for prior authorization either. A prescriber cannot submit a PA request to get an exception approved.
This is allowed under federal law. The Medicaid Drug Rebate Program at 42 U.S.C. ยง 1396r-8 generally requires states to cover nearly all FDA-approved medications, but a long-standing statutory carve-out lets states exclude drugs used for weight loss. Coverage is optional, and Ohio is among the majority of states that have declined it. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity, and the count has been shrinking as California, Pennsylvania, and New Hampshire dropped coverage under budget pressure.
What Ohio Medicaid Does Cover
The exclusion is specific to obesity treatment. The same molecules used in weight loss drugs are often covered when prescribed for other conditions.
GLP-1s for Type 2 Diabetes
The Ohio Medicaid Unified Preferred Drug List includes GLP-1 receptor agonists such as Ozempic (semaglutide), Mounjaro (tirzepatide), and Trulicity (dulaglutide) for diabetes management. Most require prior authorization, and as of December 2025 claims for certain preferred GLP-1s must include documentation of a type 2 diabetes diagnosis in the patient’s medical record.
The distinction between diabetes and weight loss matters because it often comes down to the label on the box. Semaglutide is sold as Ozempic for diabetes and as Wegovy for weight management. Ohio Medicaid covers the diabetes indication and not the weight loss indication, even though the active ingredient is the same.
Wegovy for Heart Disease or Liver Disease
In April 2026, Ohio Medicaid opened a narrow coverage pathway for Wegovy, but not for weight loss. Coverage is limited to two clinical uses: reducing the risk of major adverse cardiovascular events in patients with established heart disease, and treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of liver disease.
For cardiovascular risk reduction, the patient must be at least 18 years old, have a BMI of 27 or higher, and have a documented history of a prior heart attack, stroke, or symptomatic peripheral artery disease. The patient must already be on standard cardiovascular treatments (antiplatelet therapy, a cholesterol-lowering drug, and blood pressure medication) or have documented reasons those treatments cannot be used. The patient must not have type 1 or type 2 diabetes, confirmed by an A1C below 6.5%.
For MASH, the patient must have a confirmed diagnosis of non-cirrhotic MASH with moderate to advanced liver fibrosis (stage F2 or F3), verified by a liver biopsy within the prior two years or a combination of non-invasive tests. The prescriber must attest that the patient is following a reduced-calorie diet and exercise plan.
Authorizations last 180 days in both cases. Renewal requires at least 5% weight loss from the starting weight, medication adherence of at least 80%, and a continued A1C below 6.5%. MASH patients also need evidence that the liver disease is improving. The coverage cannot be combined with any other GLP-1 medication.
Why Switching Managed Care Plans Won’t Help
Ohio operates under a Unified Preferred Drug List that applies to every Medicaid enrollee, and a single pharmacy benefit manager, Gainwell Technologies, administers the pharmacy benefit across the entire Medicaid population. CareSource, UnitedHealthcare Community Plan, Molina, and the other managed care organizations all follow the same drug list and the same exclusions. There is no plan you can switch to that covers obesity drugs.
To check whether a specific drug is covered, you can call Gainwell Technologies Member Services at 1-833-491-0344 or look up the preferred drug list on the Ohio Department of Medicaid website.
Bariatric Surgery Is Covered
Although obesity drugs are excluded, Ohio Medicaid does cover bariatric surgery for qualifying patients. Eligibility has historically required a BMI of 40 or higher, or a BMI of 35 or higher with at least one serious obesity-related condition such as obstructive sleep apnea or poorly controlled hypertension. Patients with a BMI above 30 and inadequately controlled type 2 diabetes have also been eligible. Candidates must document at least six months of unsuccessful medically supervised weight loss attempts within the prior two years, undergo a psychological evaluation, and meet other clinical requirements.
Coverage determinations rely on clinical criteria in each managed care plan’s medical policy. Procedures considered experimental, including intragastric balloons and endoscopic sleeve gastroplasty, are excluded.
Children May Be a Different Story
Federal law requires state Medicaid programs to cover medically necessary treatments for children under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit. In principle, if an obesity medication is deemed medically necessary for a specific child, coverage could be required despite the general exclusion. One news report indicated that Ohio Medicaid covers GLP-1 drugs for a small group of children with obesity, though the specific criteria and how often this occurs are not publicly detailed.
Don’t Confuse This With the State Employee Plan
The State of Ohio employee benefits plan, administered by the Department of Administrative Services, is a separate program from Ohio Medicaid. The employee plan dropped coverage for GLP-1 weight loss medications effective July 1, 2025, and later launched a limited reimbursement program in October 2025 capped at 2,500 employees with a member cost of roughly $299 per month. Those decisions do not affect Ohio Medicaid coverage in either direction.
Paying Out of Pocket
List prices for brand-name GLP-1 medications run over $1,000 per month, which puts them out of reach for most Medicaid enrollees. Ohio law does permit physicians to prescribe GLP-1 medications via telehealth without a prior in-person visit, which can reduce the cost of getting a prescription, but the drug itself remains a cash expense.
Compounded versions of semaglutide and tirzepatide were once a lower-cost route. After the FDA resolved its GLP-1 drug shortages in spring 2025, general compounding of these medications became prohibited. The Ohio Board of Pharmacy issued guidance in July 2025 clarifying that compounding is now allowed only when a prescriber documents a “significant difference” for an individual patient compared to the commercial product, such as an allergy to a dye in the brand-name version or a need for a dosage form that does not exist commercially. Wanting a cheaper version is not a qualifying reason.
What Could Change
In December 2025, the Trump administration introduced the BALANCE model, a five-year voluntary program run through the CMS Innovation Center that aims to negotiate lower GLP-1 prices from Eli Lilly and Novo Nordisk for participating state Medicaid programs. The model began accepting state applications in 2026, with coverage expansions expected to start in May 2026 and the program running through December 2031. Whether Ohio will participate is not yet clear. Until the state opts in or the underlying rule changes, the exclusion in 5160-9-03 stands.